Objectives: To evaluate the cost-benefit ratio of measles-mumps-rubella vaccination in two Italian areas with different immunisation coverages. Design: On the basis of the epidemiologic patterns of the three diseases and vaccination were estimated. A hypothetical 5-years vaccination program for children between 2 and 6 years of age was designed for the two regions. Setting: Piemonte and Puglia regions from 1995 to 1999, with a MMR immunization coverage of 60% and 40%, respectively. Main outcome measures and results: The variation of the cost-benefit ratio of vaccination was related to immunization coverage (and residual morbidity), cost of the disease (especially indirect costs), efficacy of the vaccine. The ratio was >1 when coverage was moderate (40%) with high morbidity and low costs of the disease; with a 60% coverage a ratio of 0.70-0.90 was achieved. Conclusions: The analysis showed that the cost-benefit ratio is affected by several factors that can vary within the regional situations. While the cost of a prevented case can be low, public health strategies should also consider the cost of residual cases, which can be high when immunisation coverage or vaccine efficacy is low.

Valutazione economica della vaccinazione antimorbillo-parotite-rosolia in relazione al livello di copertura vaccinale.

DE DONNO, Maria Antonella;GUIDO, Marcello
2003-01-01

Abstract

Objectives: To evaluate the cost-benefit ratio of measles-mumps-rubella vaccination in two Italian areas with different immunisation coverages. Design: On the basis of the epidemiologic patterns of the three diseases and vaccination were estimated. A hypothetical 5-years vaccination program for children between 2 and 6 years of age was designed for the two regions. Setting: Piemonte and Puglia regions from 1995 to 1999, with a MMR immunization coverage of 60% and 40%, respectively. Main outcome measures and results: The variation of the cost-benefit ratio of vaccination was related to immunization coverage (and residual morbidity), cost of the disease (especially indirect costs), efficacy of the vaccine. The ratio was >1 when coverage was moderate (40%) with high morbidity and low costs of the disease; with a 60% coverage a ratio of 0.70-0.90 was achieved. Conclusions: The analysis showed that the cost-benefit ratio is affected by several factors that can vary within the regional situations. While the cost of a prevented case can be low, public health strategies should also consider the cost of residual cases, which can be high when immunisation coverage or vaccine efficacy is low.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11587/102799
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact